119 related articles for article (PubMed ID: 37184630)
1. Real-World Patterns of Basal Insulin Use with Other Diabetes Medications Among People with Type 2 Diabetes Between 2014 and 2020.
Schapiro D; Juneja R; Huang A; Meeks A; Liu D; Gelsey FT; Perez-Nieves M
Diabetes Ther; 2023 Jul; 14(7):1157-1174. PubMed ID: 37184630
[TBL] [Abstract][Full Text] [Related]
2. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
Monda VM; Voci C; Strollo F; Passaro A; Greco S; Monesi M; Bigoni R; Porcellati F; Piani D; Satta E; Gentile S
Diabetes Ther; 2023 Dec; 14(12):2127-2142. PubMed ID: 37801224
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
Marfella R; Prattichizzo F; Sardu C; Rambaldi PF; Fumagalli C; Marfella LV; La Grotta R; Frigé C; Pellegrini V; D'Andrea D; Cesaro A; Calabrò P; Pizzi C; Antonicelli R; Ceriello A; Mauro C; Paolisso G
Cardiovasc Diabetol; 2024 Jan; 23(1):10. PubMed ID: 38184582
[TBL] [Abstract][Full Text] [Related]
4. Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States.
Nargesi AA; Clark C; Aminorroaya A; Chen L; Liu M; Reddy A; Amodeo S; Oikonomou EK; Suchard MA; McGuire DK; Lin Z; Inzucchi S; Khera R
Am J Cardiol; 2023 Jun; 196():89-98. PubMed ID: 37012183
[TBL] [Abstract][Full Text] [Related]
5. Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents.
Zhang T; Zullo AR; Hayes KKN; Kim DH; Lee Y; Daiello LA; Kiel DP; Berry SD
J Am Med Dir Assoc; 2024 Mar; 25(3):454-458. PubMed ID: 37553080
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes.
Nørgaard CH; Starkopf L; Gerds TA; Vestergaard P; Bonde AN; Fosbøl E; Køber L; Wong ND; Torp-Pedersen C; Lee CJ
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):549-556. PubMed ID: 34215881
[TBL] [Abstract][Full Text] [Related]
7. Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity.
Klein KR; Abrahamsen TJ; Kahkoska AR; Alexander GC; Chute CG; Haendel M; Hong SS; Mehta H; Moffitt R; Stürmer T; Kvist K; Buse JB;
Diabetes Ther; 2024 May; 15(5):1169-1186. PubMed ID: 38536629
[TBL] [Abstract][Full Text] [Related]
8. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.
Caruso I; Di Gioia L; Di Molfetta S; Cignarelli A; Palmer SC; Natale P; Strippoli GFM; Perrini S; Natalicchio A; Laviola L; Giorgino F
EClinicalMedicine; 2023 Oct; 64():102181. PubMed ID: 37719418
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.
Weng W; Tian Y; Kong SX; Ganguly R; Hersloev M; Brett J; Hobbs T
Endocrinol Diabetes Metab; 2019 Jul; 2(3):e00076. PubMed ID: 31294089
[TBL] [Abstract][Full Text] [Related]
10. Factors Influencing the Choice of Glucose-Lowering Medications Among Physicians Treating Patients With Type 2 Diabetes.
AlSofiani ME; AlHalees DZ; Aljebreen JA; Abu Dahesh JA; Bamogaddam GS; AlBraithen GM; Jammah A
Cureus; 2024 Feb; 16(2):e53844. PubMed ID: 38465107
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
Dankner R; Murad H; Agay N; Olmer L; Freedman LS
JAMA Netw Open; 2024 Jan; 7(1):e2350408. PubMed ID: 38175642
[TBL] [Abstract][Full Text] [Related]
12. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis.
Bilal A; Yi F; Gonzalez GR; Ali M; Im K; Ruff CT; Thethi TK; Pratley RE
J Diabetes Complications; 2024 Jun; 38(8):108783. PubMed ID: 38870731
[TBL] [Abstract][Full Text] [Related]
13. New Diabetes Guidelines: Impact on Eligibility for Sodium-glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada.
Bodoarca R; Yeung RO; Lau D
Can J Diabetes; 2022 Apr; ():. PubMed ID: 35940961
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.
Chen Y; Chen J; Zhang S; Zhu D; Deng F; Zuo R; Hu Y; Zhao Y; Duan Y; Lin B; Chen F; Liang Y; Zheng J; Khan BA; Hou K
Front Pharmacol; 2024; 15():1370594. PubMed ID: 38515845
[No Abstract] [Full Text] [Related]
15. Sociodemographic Disparities in Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Prescription Patterns Among Patients With Poorly Controlled Diabetes.
Antwi-Amoabeng D; Beutler BD; Ghuman J; Ulanja MB; Ghuman J; Gullapalli N
Cureus; 2024 Mar; 16(3):e56845. PubMed ID: 38659524
[TBL] [Abstract][Full Text] [Related]
16. Achieving Good Metabolic Control Without Weight Gain with the Systematic Use of GLP-1-RAs and SGLT-2 Inhibitors in Type 2 Diabetes: A Machine-learning Projection Using Data from Clinical Practice.
Giorda CB; Rossi A; Baccetti F; Zilich R; Romeo F; Besmir N; Di Cianni G; Guaita G; Morviducci L; Muselli M; Ozzello A; Pisani F; Ponzani P; Santin P; Verda D; Musacchio N
Clin Ther; 2023 Aug; 45(8):754-761. PubMed ID: 37451913
[TBL] [Abstract][Full Text] [Related]
17. Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study.
Skriver C; Friis S; Knudsen LB; Catarig AM; Clark AJ; Dehlendorff C; Mørch LS
Diabetologia; 2023 Nov; 66(11):2007-2016. PubMed ID: 37532786
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy.
Gosmanov AR; Gemoets DE; Schumacher KA
J Endocrinol Invest; 2024 Mar; ():. PubMed ID: 38536657
[TBL] [Abstract][Full Text] [Related]
19. GLP-1RA therapy increases circulating vascular regenerative cell contentin people living with type 2 diabetes.
Park B; Krishnaraj A; Teoh H; Bakbak E; Dennis F; Quan A; Hess DA; Verma S
Am J Physiol Heart Circ Physiol; 2024 Jun; ():. PubMed ID: 38874618
[TBL] [Abstract][Full Text] [Related]
20. Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes.
Wang L; Berger NA; Kaelber DC; Xu R
Gastroenterology; 2024 Apr; ():. PubMed ID: 38692395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
